Glucose targets for preventing diabetic kidney disease and its progression

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 6, 2017, Pages

  Ruospo, Marinella ^a,b   Saglimbene, Valeria M ^a   Palmer, Suetonia C ^c   De Cosmo, Salvatore ^d   Pacilli, Antonio ^d   Lamacchia, Olga ^e   Cignarelli, Mauro ^e   Fioretto, Paola ^f   Vecchio, Mariacristina ^g   Craig, Jonathan C ^h,i   Strippoli, Giovanni F M ^a,i,j,k  

^a Diaverum   (Sweden)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c UNIVERSITY OF OTAGO   (New Zealand)

^d CSS Scientific Institute   (Italy)

^e UNIVERSITY OF FOGGIA   (Italy)

^f UNIVERSITY OF PADOVA   (Italy)

^g Danone Research   (France)

^h UNIVERSITY OF SYDNEY   (Australia)

ⁱ University of Sydney   (Australia)

^j UNIVERSITY OF BARI   (Italy)

^k Diaverum Academy   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; CREATININE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PROTEIN KINASE C; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

AGE DISTRIBUTION; CARDIOVASCULAR MORTALITY; CHOLESTEROL BLOOD LEVEL; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE COURSE; EVIDENCE BASED MEDICINE; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LIFE EXPECTANCY; MICROALBUMINURIA; MORTALITY RATE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SYSTEMATIC REVIEW; TREATMENT DURATION; ALBUMINURIA; BLOOD; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; COMPLICATION; DIABETIC NEPHROPATHIES; DIET RESTRICTION; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; KIDNEY FAILURE, CHRONIC; META ANALYSIS; MORTALITY; MYOCARDIAL INFARCTION; STROKE; SUDDEN DEATH; TIME FACTOR;

ALBUMINURIA; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; CREATININE; DEATH, SUDDEN; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FASTING; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; KIDNEY FAILURE, CHRONIC; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; TIME FACTORS;

EID: 85020461115     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010137.pub2     Document Type: Review

References (234)

1. ACCORD Study Group, ACCORD Eye Study Group, Chew EY, Ambrosius WT, Davis MD, Danis RP, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes.[Erratum appears in N Engl J Med. 2011 Jan 13;364(2):190], [Erratum appears in N Engl J Med. 2012 Dec 20;367(25):2458]. New England Journal of Medicine 2010;363(3):233-44. [MEDLINE: 20587587]5656181
2. ACCORD Study Group, Buse JB, Bigger JT, Byington RP, Cooper LS, Cushman WC, et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. American Journal of Cardiology 2007;99(12A):21i-33i. [MEDLINE: 17599422]5656182
3. ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. New England Journal of Medicine 2010;362(17):1575-85. [MEDLINE: 20228401]5656183
4. ACCORD Study Group, Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. New England Journal of Medicine 2011;364(9):818-28. [MEDLINE: 21366473]5656184
5. ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, et al. Effects of combination lipid therapy in type 2 diabetes mellitus.[Erratum appears in N Engl J Med. 2010 May 6;362(18):1748]. New England Journal of Medicine 2010;362(17):1563-74. [MEDLINE: 20228404]5656185
6. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, et al. Effects of intensive glucose lowering in type 2 diabetes. New England Journal of Medicine 2008;358(24):2545-59. [MEDLINE: 18539917]5656186
7. Barzilay JI, Howard AG, Evans GW, Fleg JL, Cohen RM, Booth GL, et al. Intensive blood pressure treatment does not improve cardiovascular outcomes in centrally obese hypertensive individuals with diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Blood Pressure Trial. Diabetes Care 2012;35(7):1401-5. [MEDLINE: 22723577]5656187
8. Barzilay JI, Lovato JF, Murray AM, Williamson J, Ismail-Beigi F, Karl D, et al. Albuminuria and cognitive decline in people with diabetes and normal renal function. Clinical Journal of the American Society of Nephrology: CJASN 2013;8(11):1907-14. [MEDLINE: 23990163]5656188
9. Bonds DE, Craven TE, Buse J, Crouse JR, Cuddihy R, Elam M, et al. Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience. Diabetologia 2012;55(6):1641-50. [MEDLINE: 22450889]5656189
10. Bonds DE, Kurashige EM, Bergenstal R, Brillon D, Domanski M, Felicetta JV, et al. Severe hypoglycemia monitoring and risk management procedures in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology 2007;99(12A):80i-9i. [MEDLINE: 17599428]5656190
11. Bonds DE, Miller ME, Bergenstal RM, Buse JB, Byington RP, Cutler JA, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010;340:b4909. [MEDLINE: 20061358]5656191
12. Bonds DE, Miller ME, Dudl J, Feinglos M, Ismail-Beigi F, Malozowski S, et al. Severe hypoglycemia symptoms, antecedent behaviors, immediate consequences and association with glycemia medication usage: Secondary analysis of the ACCORD clinical trial data. BMC Endocrine Disorders 2012;12:5. [MEDLINE: 22646230]5656192
13. Chew EY, Ambrosius WT, Howard LT, Greven CM, Johnson S, Danis RP, et al. Rationale, design, and methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD-EYE). American Journal of Cardiology 2007;99(12A):103i-11i. [MEDLINE: 17599420]5656193
14. Cushman WC, Grimm RH Jr, Cutler JA, Evans GW, Capes S, Corson MA, et al. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology 2007;99(12A):44i-55i. [MEDLINE: 17599425]5656194
15. Fatemi O, Yuriditsky E, Tsioufis C, Tsachris D, Morgan T, Basile J, et al. Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study). American Journal of Cardiology 2014;114(8):1217-22. [MEDLINE: 25159234]5656195
16. Fonseca V, McDuffie R, Calles J, Cohen RM, Feeney P, Feinglos M, et al. Determinants of weight gain in the action to control cardiovascular risk in diabetes trial. Diabetes Care 2013;36(8):2162-8. [MEDLINE: 23412077]5656196
17. Genuth S, Ismail-Beigi F. Clinical implications of the ACCORD trial. Journal of Clinical Endocrinology & Metabolism 2012;97(1):41-8. [MEDLINE: 22049171]5656197
18. Gerstein HC, Ambrosius WT, Danis R, Ismail-Beigi F, Cushman W, Calles J, et al. Diabetic retinopathy, its progression, and incident cardiovascular events in the ACCORD trial. Diabetes Care 2013;36(5):1266-71. [MEDLINE: 23238658]5656198
19. Gerstein HC, Miller ME, Ismail-Beigi F, Largay J, McDonald C, Lochnan HA, et al. Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial. Lancet 2014;384(9958):1936-41. [MEDLINE: 25088437]5656199
20. Gerstein HC, Riddle MC, Kendall DM, Cohen RM, Goland R, Feinglos MN, et al. Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology 2007;99(12A):34i-43i. [MEDLINE: 17599423]5656200
21. Ginsberg HN, Bonds DE, Lovato LC, Crouse JR, Elam MB, Linz PE, et al. Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology 2007;99(12A):56i-67i. [MEDLINE: 17599426]5656201
22. Goff DC Jr, Gerstein HC, Ginsberg HN, Cushman WC, Margolis KL, Byington RP, et al. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology 2007;99(12A):4i-20i. [MEDLINE: 17599424]5656202
23. Isakova T, Craven TE, Scialla JJ, Nickolas TL, Schnall A, Barzilay J, et al. Change in estimated glomerular filtration rate and fracture risk in the Action to Control Cardiovascular Risk in Diabetes Trial. Bone 2015;78:23-7. [MEDLINE: 25937184]5656203
24. Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.[Erratum appears in Lancet. 2010 Oct 30;376(9751):1466]. Lancet 2010;376(9739):419-30. [MEDLINE: 20594588]5656204
25. Ismail-Beigi F, Craven TE, O'Connor PJ, Karl D, Calles-Escandon J, Hramiak I, et al. Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. Kidney International 2012;81(6):586-94. [MEDLINE: 22166848]5656205
26. Kingry C, Bastien A, Booth G, Geraci TS, Kirpach BR, Lovato LC, et al. Recruitment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology 2007;99(12A):68i-79i. [MEDLINE: 17599427]5656206
27. Linz PE, Lovato LC, Byington RP, O'Connor PJ, Leiter LA, Weiss D, et al. Paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial. Diabetes Care 2014;37(3):686-93. [MEDLINE: 24296848]5656207
28. Margolis KL, O'Connor PJ, Morgan TM, Buse JB, Cohen RM, Cushman WC, et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care 2014;37(6):1721-8. [MEDLINE: 24595629]5656208
29. Meier M, Hummel M. Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies. Vascular Health & Risk Management 2009;5:859-71. [MEDLINE: 19898642]5656209
30. Miller ME, Bonds DE, Gerstein HC, Seaquist ER, Bergenstal RM, Calles-Escandon J, et al. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ 2010;340:b5444. [MEDLINE: 20061360]5656210
31. Miller ME, Williamson JD, Gerstein HC, Byington RP, Cushman WC, Ginsberg HN, et al. Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial. Diabetes Care 2014;37(3):634-43. [MEDLINE: 24170759]5656211
32. Mottl AK, Pajewski N, Fonseca V, Ismail-Beigi F, Chew E, Ambrosius WT, et al. The degree of retinopathy is equally predictive for renal and macrovascular outcomes in the ACCORD Trial. Journal of Diabetes & its Complications 2014;28(6):874-9. [MEDLINE: 25123755]5656212
33. Mychaleckyj JC, Craven T, Nayak U, Buse J, Crouse JR, Elam M, et al. Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants. Diabetes Care 2012;35(5):1008-14. [MEDLINE: 22432114]5656213
34. Mychaleckyj JC, Farber EA, Chmielewski J, Artale J, Light LS, Bowden DW, et al. Buffy coat specimens remain viable as a DNA source for highly multiplexed genome-wide genetic tests after long term storage. Journal of Translational Medicine 2011;9:91. [MEDLINE: 21663644]5656214
35. Nadkarni GN, Rao V, Ismail-Beigi F, Fonseca VA, Shah SV, Simonson MS, et al. Association of urinary biomarkers of inflammation, injury, and fibrosis with renal function decline: The ACCORD Trial. Clinical Journal of the American Society of Nephrology: CJASN 2016;11(8):1343-52. [MEDLINE: 27189318]5656215
36. Papademetriou V, Lovato L, Doumas M, Nylen E, Mottl A, Cohen RM, et al. Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes. Kidney International 2015;87(3):649-59. [MEDLINE: 25229335]5656216
37. Pop-Busui R, Evans GW, Gerstein HC, Fonseca V, Fleg JL, Hoogwerf BJ, et al. Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care 2010;33(7):1578-84. [MEDLINE: 20215456]5656217
38. Punthakee Z, Miller ME, Launer LJ, Williamson JD, Lazar RM, Cukierman-Yaffee T, et al. Poor cognitive function and risk of severe hypoglycemia in type 2 diabetes: post hoc epidemiologic analysis of the ACCORD trial. Diabetes Care 2012;35(4):787-93. [MEDLINE: 22374637]5656218
39. Raisch DW, Feeney P, Goff DC Jr, Narayan KM, O'Connor PJ, Zhang P, et al. Baseline comparison of three health utility measures and the feeling thermometer among participants in the Action to Control Cardiovascular Risk in Diabetes trial. Cardiovascular Diabetology 2012;11:35. [MEDLINE: 22515638]5656219
40. Reyes-Soffer G, Ngai CI, Lovato L, Karmally W, Ramakrishnan R, Holleran S, et al. Effect of combination therapy with fenofibrate and simvastatin on postprandial lipemia in the ACCORD lipid trial. Diabetes Care 2013;36(2):422-8. [MEDLINE: 23033246]5656220
41. Riddle MC, Ambrosius WT, Brillon DJ, Buse JB, Byington RP, Cohen RM, et al. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 2010;33(5):983-90. [MEDLINE: 20427682]5656221
42. Samaropoulos XF, Light L, Ambrosius WT, Marcovina SM, Probstfield J, Jr DC. The effect of intensive risk factor management in type 2 diabetes on inflammatory biomarkers. Diabetes Research & Clinical Practice 2012;95(3):389-98. [MEDLINE: 22019270]5656222
43. Seaquist ER, Miller ME, Bonds DE, Feinglos M, Goff DC Jr, Peterson K, et al. The impact of frequent and unrecognized hypoglycemia on mortality in the ACCORD study. Diabetes Care 2012;35(2):409-14. [MEDLINE: 22179956]5656223
44. Strylewicz G, Doctor J. Evaluation of an automated method to assist with error detection in the ACCORD central laboratory. Clinical Trials 2010;7(4):380-9. [MEDLINE: 20571135]5656224
45. Sullivan MD, Anderson RT, Aron D, Atkinson HH, Bastien A, Chen GJ, et al. Health-related quality of life and cost-effectiveness components of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: rationale and design. American Journal of Cardiology 2007;99(12A):90i-102i. [MEDLINE: 17599429]5656225
46. Sullivan MD, O'Connor P, Feeney P, Hire D, Simmons DL, Raisch DW, et al. Depression predicts all-cause mortality: epidemiological evaluation from the ACCORD HRQL substudy. Diabetes Care 2012;35(8):1708-15. [MEDLINE: 22619083]5656226
47. Thethi T, Rajapurkar M, Walker P, McDuffie R, Goff DC Jr, Probstfield J, et al. Urinary catalytic iron in patients with type 2 diabetes without microalbuminuria--a substudy of the ACCORD Trial. Clinical Chemistry 2011;57(2):341-4. [MEDLINE: 21159897]5656227
48. Williamson JD, Launer LJ, Bryan RN, Coker LH, Lazar RM, Gerstein HC, et al. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Internal Medicine 2014;174(3):324-33. [MEDLINE: 24493100]5656228
49. Williamson JD, Miller ME, Bryan RN, Lazar RM, Coker LH, Johnson J, et al. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods. American Journal of Cardiology 2007;99(12A):112i-22i. [MEDLINE: 17599421]5656229
50. Rationale and design of the ADVANCE study: a randomised trial of blood pressure lowering and intensive glucose control in high-risk individuals with type 2 diabetes mellitus. Action in Diabetes and Vascular Disease: Preterax and diamicron modified-release controlled evaluation. Journal of Hypertension - Supplement 2001;19(4):S21-8. [MEDLINE: 11848259]5656252
51. ADVANCE Collaborative Group. ADVANCE--Action in Diabetes and Vascular Disease: patient recruitment and characteristics of the study population at baseline. Diabetic Medicine 2005;22(7):882-8. [MEDLINE: 15975103]5656232
52. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New England Journal of Medicine 2008;358(24):2560-72. [MEDLINE: 18539916]5656231
53. ADVANCE Management Committee. Study rationale and design of ADVANCE: action in diabetes and vascular disease--Preterax and Diamicron MR Controlled Evaluation. Diabetologia 2001;44(9):1118-20. [MEDLINE: 11596665]5656233
54. Blomster JI, Woodward M, Zoungas S, Hillis GS, Harrap S, Neal B, et al. The harms of smoking and benefits of smoking cessation in women compared with men with type 2 diabetes: an observational analysis of the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron modified release Controlled Evaluation) trial. BMJ Open 2016;6(1):e009668. [MEDLINE: 26747037]5656234
55. Chalmers J. ADVANCE study: objectives, design and current status [Etude ADVANCE: objectifs, protocole et etat actuel]. Drugs 2003;63(Spec No 1):39-44. [MEDLINE: 12708881]5656237
56. Chalmers J, Marre M, de Galan BE, Zoungas S, Hamet P, Neal B, et al. The efficacy of lowering HbAlc with a gliclazide modified release-based intensive glucose lowering regimen in the ADVANCE trial [abstract]. Diabetologia 2009;52(Suppl 1):S354. [EMBASE: 70068392]5656235
57. Chalmers J, Perkovic V, Joshi R, Patel A. ADVANCE: breaking new ground in type 2 diabetes. Journal of Hypertension - Supplement 2006;24(5):S22-S8. [MEDLINE: 16936533]5656236
58. Cooper ME, Zoungas S, Jardine M, Hata J, Perkovic V, Ninomiya T, et al. Risk of major renal events in people with type 2 diabetes: prediction models based on the ADVANCE study population [abstract]. Diabetologia 2011;54(1 Suppl):S442. [EMBASE: 70563236]5656238
59. Hata J, Arima H, Rothwell PM, Woodward M, Zoungas S, Anderson C, et al. Effects of visit-to-visit variability in systolic blood pressure on macrovascular and microvascular complications in patients with type 2 diabetes mellitus: the ADVANCE trial. Circulation 2013;128(12):1325-34. [MEDLINE: 23926207]5656239
60. Heerspink HJ, Ninomiya T, Perkovic V, Woodward M, Zoungas S, Cass A, et al. Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. European Heart Journal 2010;31(23):2888-96. [MEDLINE: 20501479]5656240
61. Jardine M, Ninomiya T, Perkovic V, Woodward M, Pillai A, Cass A, et al. Predictive baseline factors for major renal events: a proportional hazards model based on the ADVANCE Study [abstract no: F-PO1916]. Journal of the American Society of Nephrology 2008;19(Abstracts Issue):543A. [CENTRAL: CN-00724903]5656241
62. Jardine MJ, Hata J, Woodward M, Perkovic V, Ninomiya T, Arima H, et al. Prediction of kidney-related outcomes in patients with type 2 diabetes. American Journal of Kidney Diseases 2012;60(5):770-8. [MEDLINE: 22694950]5656242
63. Mohammedi K, Woodward M, Hirakawa Y, Zoungas S, Colagiuri S, Hamet P, et al. Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE-ON study. Cardiovascular Diabetology 2016;15(1):129. [MEDLINE: 27590190]5656243
64. Ninomiya T, Zoungas S, Neal B, Woodward M, Patel A, Perkovic V, et al. Efficacy and safety of routine blood pressure lowering in older patients with diabetes: results from the ADVANCE trial. Journal of Hypertension 2010;28(6):1141-9. [MEDLINE: 20486273]5656244
65. Patel A, ADVANCE Collaborative Group, MacMahon S, Chalmers J, Neal B, Woodward M, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370(9590):829-40. [MEDLINE: 17765963]5656245
66. Patel A, Chalmers J, Poulter N. ADVANCE: action in diabetes and vascular disease. Journal of Human Hypertension 2005;19 Suppl 1:S27-32. [MEDLINE: 16075030]5656246
67. Perkovic V, Heerspink HL, Chalmers J, Woodward M, Jun M, Li Q, et al. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney International 2013;83(3):517-23. [MEDLINE: 23302714]5656247
68. Perkovic V, Ninomiya T, de Galan BE, Zoungas S, Cass A, Patel A, et al. Joint effects of routine blood pressure lowering and intensive glucose control in the ADVANCE trial [abstract no: LB-002]. American Society of Nephrology (ASN) Renal Week; 2008 Nov 4-9; Philadelphia, PA. 2008. [CENTRAL: CN-00740604]5656248
69. Perkovic V, Zoungas S, Heerspink HL, Woodward M, Jun M, Cass A, et al. Intensive glucose lowering and end stage kidney disease - new data from the ADVANCE trial [abstract no: 071]. Nephrology 2011;16(Suppl 1):42. [EMBASE: 70532419]5656249
70. Perkovic V, de Galan B, Chalmers J, Ninomiya T, Patel A, Cass A, et al. Renoprotection with perindopril-indapamide below current recommended blood pressure targets in patients with type 2 diabetes mellitus: results of the ADVANCE trial [abstract no: 085]. Nephrology 2008;13(Suppl 3):A121. [CENTRAL: CN-00740462]5656250
71. Poulter NR. Blood pressure and glucose control in subjects with diabetes: new analyses from ADVANCE. Journal of Hypertension - Supplement 2009;27(1):S3-8. [MEDLINE: 19483505]5656251
72. Wong G, Zoungas S, Lo S, Chalmers J, Cass A, Neal B, et al. The risk of cancer in people with diabetes and chronic kidney disease. Nephrology Dialysis Transplantation 2012;27(8):3337-44. [MEDLINE: 22357699]5656253
73. Wong MG, Perkovic V, Chalmers J, Woodward M, Li Q, Cooper ME, et al. Long-term benefits of intensive glucose control for preventing end-stage kidney disease: ADVANCE-ON. Diabetes Care 2016;39(5):694-700. [MEDLINE: 27006512]5656254
74. Zoungas S, Chalmers J, Ninomiya T, Li Q, Cooper ME, Colagiuri S, et al. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia 2012;55(3):636-43. [MEDLINE: 22186981]5656255
75. Zoungas S, Lambers Heerspink HJ, Chalmers J, Woodward M, Jun M, Cass A, et al. Intensive glucose lowering and end stage kidney disease: new data from the ADVANCE trial [abstract]. Diabetologia 2011;54(1 Suppl):S23. [EMBASE: 70562184]5656256
76. Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L, et al. Severe hypoglycemia and risks of vascular events and death. New England Journal of Medicine 2010;363(15):1410-8. [MEDLINE: 20925543]5656257
77. Zoungas S, Perkovic V, Ninomiya T, de Galan BE, Pillai I, Patel A, et al. Joint effects of blood pressure lowering and glucose control in the ADVANCE trial [abstract]. Hypertension 2009;53(6):1103. [EMBASE: 70036220]5656258
78. Zoungas S, de Galan BE, Ninomiya T, Grobbee D, Hamet P, Heller S, et al. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: new results from the ADVANCE trial. Diabetes Care 2009;32(11):2068-74. [MEDLINE: 19651921]5656259
79. de Galan BE, Ninomiya T, Perrovic V, Pillai A, Patel A, Neal ACB, et al. Renoprotective effects of blood pressure lowering with perindopril-indapamide below current targets in people with type 2 diabetes mellitus: Results of the ADVANCE trial [abstract]. Diabetes 2008;57(Suppl 1):A218-9. [CENTRAL: CN-00757885]5656260
80. de Galan BE, Perkovic V, Ninomiya T, Pillai A, Patel A, Cass A, et al. Lowering blood pressure reduces renal events in type 2 diabetes. Journal of the American Society of Nephrology 2009;20(4):883-92. [MEDLINE: 19225038]5656261
81. Ciavarella A, Vannini P, Flammini M, Bacci L, Forlani G, Borgnino LC. Effect of long-term near-normoglycemia on the progression of diabetic nephropathy. Diabete et Metabolisme 1985;11(1):3-8. [MEDLINE: 3884404]5656263
82. Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. The DCCT Research Group. Diabetes 1986;35(5):530-45. [MEDLINE: 2869996]5656269
83. Diabetes Control and Complications Trial (DCCT). Update. DCCT Research Group. Diabetes Care 1990;13(4):427-33. [MEDLINE: 2180661]5656270
84. Diabetes Control and Complications Trial (DCCT): results of feasibility study. The DCCT Research Group. Diabetes Care 1987;10(1):1-19. [MEDLINE: 2882967]5656271
85. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. Journal of Pediatrics 1994;125(2):177-88. [MEDLINE: 8040759]5656273
86. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney International 1995;47(6):1703-20. [MEDLINE: 7643540]5656274
87. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group.[Erratum appears in N Engl J Med 2000 May 4;342(18):1376]. New England Journal of Medicine 2000;342(6):381-9. [MEDLINE: 10666428]5656295
88. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. New England Journal of Medicine 1993;329(14):977-86. [MEDLINE: 8366922]5656298
89. Al-Kateb H, Boright AP, Mirea L, Xie X, Sutradhar R, Mowjoodi A, et al. Multiple superoxide dismutase 1/splicing factor serine alanine 15 variants are associated with the development and progression of diabetic nephropathy: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Genetics study. Diabetes 2008;57(1):218-28. [MEDLINE: 17914031]5656265
90. DCCT/EDIC Research Group. Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study. The Lancet Diabetes & Endocrinology 2014;2(10):793-800. [MEDLINE: 25043685]5656268
91. DCCT/EDIC Research Group, Aiello LP, Sun W, Das A, Gangaputra S, Kiss S, et al. Intensive diabetes therapy and ocular surgery in type 1 diabetes. New England Journal of Medicine 2015;372(18):1722-33. [MEDLINE: 25923552]5656266
92. DCCT/EDIC Research Group, de Boer IH, Sun W, Cleary PA, Lachin JM, Molitch ME, et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. New England Journal of Medicine 2011;365(25):2366-76. [MEDLINE: 22077236]5656267
93. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group, Nathan DM, Zinman B, Cleary PA, Backlund JY, Genuth S, et al. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Archives of Internal Medicine 2009;169(14):1307-16. [MEDLINE: 19636033]5656272
94. Gai N, Turkbey EB, Nazarian S, van der Geest RJ, Liu CY, Lima JA, et al. T1 mapping of the gadolinium-enhanced myocardium: adjustment for factors affecting interpatient comparison. Magnetic Resonance in Medicine 2011;65(5):1407-15. [MEDLINE: 21500267]5656275
95. Gubitosi-Klug RA, DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: summary and future directions. Diabetes Care 2014;37(1):44-9. [MEDLINE: 24356597]5656276
96. Hoeldtke RD, Hampe CS, Bekris LM, Hobbs G, Bryner KD, Lernmark A, et al. Antibodies to GAD65 and peripheral nerve function in the DCCT. Journal of Neuroimmunology 2007;185(1-2):182-9. [MEDLINE: 17328966]5656277
97. Jacobson AM, Braffett BH, Cleary PA, Gubitosi-Klug RA, Larkin ME, DCCT/EDIC Research Group. The long-term effects of type 1 diabetes treatment and complications on health-related quality of life: a 23-year follow-up of the Diabetes Control and Complications/Epidemiology of Diabetes Interventions and Complications cohort. Diabetes Care 2013;36(10):3131-8. [MEDLINE: 23835693]5656278
98. Jenkins AJ, Yu J, Alaupovic P, Basu A, Klein RL, Lopes-Virella M, et al. Apolipoprotein-defined lipoproteins and apolipoproteins: associations with abnormal albuminuria in type 1 diabetes in the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort. Journal of Diabetes & its Complications 2013;27(5):447-53. [MEDLINE: 23850262]5656279
99. Kilpatrick ES, Rigby AS, Atkin SL. A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial. Diabetes Care 2008;31(11):2198-202. [MEDLINE: 18650371]5656280
100. Kim C, Cleary PA, Cowie CC, Braffett BH, Dunn RL, Larkin ME, et al. Effect of glycemic treatment and microvascular complications on menopause in women with type 1 diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort. Diabetes Care 2014;37(3):701-8. [MEDLINE: 24170751]5656281
101. Klein RL, Hammad SM, Baker NL, Hunt KJ, Al Gadban MM, Cleary PA, et al. Decreased plasma levels of select very long chain ceramide species are associated with the development of nephropathy in type 1 diabetes. Metabolism: Clinical & Experimental 2014;63(10):1287-95. [MEDLINE: 25088746]5656282
102. Kramer CK, Retnakaran R. Concordance of retinopathy and nephropathy over time in Type 1 diabetes: an analysis of data from the Diabetes Control and Complications Trial. Diabetic Medicine 2013;30(11):1333-41. [MEDLINE: 23909911]5656283
103. Lachin JM, McGee P, Palmer JP, DCCT/EDIC Research Group. Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. Diabetes 2014;63(2):739-48. [MEDLINE: 24089509]5656284
104. Larkin ME, Backlund JY, Cleary P, Bayless M, Schaefer B, Canady J, et al. Disparity in management of diabetes and coronary heart disease risk factors by sex in DCCT/EDIC. Diabetic Medicine 2010;27(4):451-8. [MEDLINE: 20536518]5656285
105. Lee CC, Sharp SJ, Wexler DJ, Adler AI. Dietary intake of eicosapentaenoic and docosahexaenoic acid and diabetic nephropathy: cohort analysis of the Diabetes Control and Complications Trial. Diabetes Care 2010;33(7):1454-6. [MEDLINE: 20357378]5656286
106. Levey AS, Greene T, Schluchter MD, Cleary PA, Teschan PE, Lorenz RA, et al. Glomerular filtration rate measurements in clinical trials. Modification of Diet in Renal Disease Study Group and the Diabetes Control and Complications Trial Research Group. Journal of the American Society of Nephrology 1993;4(5):1159-71. [MEDLINE: 8305642]5656287
107. Lin J, Manson J, Schaumberg D. Inflammation and progressive nephropathy in the diabetes complication and control trial (DCCT) [abstract no: F-PO1015]. Journal of the American Society of Nephrology 2007;18(Abstracts):325A-6A. 5656288
108. Lopes-Virella MF, Baker NL, Hunt KJ, Cleary PA, Klein R, Virella G, et al. Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects. Diabetes Care 2013;36(8):2317-23. [MEDLINE: 23514730]5656289
109. Lopes-Virella MF, Carter RE, Baker NL, Lachin J, Virella G, DCCT/EDIC Research Group. High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes. Nephrology Dialysis Transplantation 2012;27(4):1416-23. [MEDLINE: 21856760]5656290
110. McGee P, Steffes M, Nowicki M, Bayless M, Gubitosi-Klug R, Cleary P, et al. Insulin secretion measured by stimulated C-peptide in long-established Type 1 diabetes in the Diabetes Control and Complications Trial (DCCT)/ Epidemiology of Diabetes Interventions and Complications (EDIC) cohort: a pilot study. Diabetic Medicine 2014;31(10):1264-8. [MEDLINE: 24836354]5656291
111. Molitch ME, Steffes M, Sun W, Rutledge B, Cleary P, de Boer IH, et al. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care 2010;33(7):1536-43. [MEDLINE: 20413518]5656292
112. Nathan DM, Steffes MW, Sun W, Rynders GP, Lachin JM. Determining stability of stored samples retrospectively: the validation of glycated albumin. Clinical Chemistry 2011;57(2):286-90. [MEDLINE: 21030684]5656293
113. Polak JF, Backlund JY, Cleary PA, Harrington AP, O'Leary DH, Lachin JM, et al. Progression of carotid artery intima-media thickness during 12 years in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. Diabetes 2011;60(2):607-13. [MEDLINE: 21270271]5656294
114. Siebert C, Clark CM Jr. Operational and policy considerations of data monitoring in clinical trials: the Diabetes Control and Complications Trial experience. Controlled Clinical Trials 1993;14(1):30-44. [MEDLINE: 8440093]5656296
115. Tello A, Mondress M, Fan Y, Thomas W, Steffes M, Ibrahim H. The utility of serum creatinine based formulas in predicting the glomerular filtration rate in Type 1 diabetics with normal serum creatinine [abstract no: SU-PO169]. Journal of the American Society of Nephrology 2004;15(Oct):569A. [CENTRAL: CN-00583257]5656297
116. Turkbey EB, Backlund JY, Genuth S, Jain A, Miao C, Cleary PA, et al. Myocardial structure, function, and scar in patients with type 1 diabetes mellitus. Circulation 2011;124(16):1737-46. [MEDLINE: 21947298]5656299
117. White NH, Sun W, Cleary PA, Danis RP, Davis MD, Hainsworth DP, et al. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Archives of Ophthalmology 2008;126(12):1707-15. [MEDLINE: 19064853]5656300
118. White NH, Sun W, Cleary PA, Tamborlane WV, Danis RP, Hainsworth DP, et al. Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents. Diabetes 2010;59(5):1244-53. [MEDLINE: 20150283]5656301
119. Younes N, Cleary PA, Steffes MW, de Boer IH, Molitch ME, Rutledge BN, et al. Comparison of urinary albumin-creatinine ratio and albumin excretion rate in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Clinical Journal of the American Society of Nephrology: CJASN 2010;5(7):1235-42. [MEDLINE: 20448066]5656302
120. de Boer IH, Afkarian M, Rue TC, Cleary PA, Lachin JM, Molitch ME, et al. Renal outcomes in patients with type 1 diabetes and macroalbuminuria. Journal of the American Society of Nephrology 2014;25(10):2342-50. [MEDLINE: 24925722]5656303
121. de Boer IH, Rue TC, Cleary PA, Lachin JM, Molitch ME, Steffes MW, et al. Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. Archives of Internal Medicine 2011;171(5):412-20. [MEDLINE: 21403038]5656304
122. de Boer IH, Sun W, Cleary PA, Lachin JM, Molitch ME, Steffes M, et al. Effects of intensive diabetes therapy on glomerular filtration rate of type 1 diabetes: results from the DCCT/EDIC [Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study] [abstract no: LB-OR05]. Journal of the American Society of Nephrology 2011;22(Abstracts):2B. 5656305
123. Feldt-Rasmussen B, Mathiesen ER, Deckert T. Effect of two years of strict metabolic control on progression of incipient nephropathy in insulin-dependent diabetes. Lancet 1986;2(8519):1300-4. [MEDLINE: 2878175]5656307
124. Feldt-Rasmussen B, Mathiesen ER, Hegedus L, Deckert T. Kidney function during 12 months of strict metabolic control in insulin-dependent diabetic patients with incipient nephropathy. New England Journal of Medicine 1986;314(11):665-70. [MEDLINE: 3513009]5656308
125. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Research & Clinical Practice 1995;28(2):103-17. [MEDLINE: 7587918]5656310
126. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000;23 Suppl 2:B21-9. [MEDLINE: 10860187]5656311
127. Wake N, Hisashige A, Katayama T, Kishikawa H, Ohkubo Y, Sakai M, et al. Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study. Diabetes Research & Clinical Practice 2000;48(3):201-10. [MEDLINE: 10802159]5656312
128. Crasto W, Jarvis J, Khunti K, Skinner TC, Gray LJ, Brela J, et al. Multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: the Microalbuminuria Education and Medication Optimisation (MEMO) study. Diabetes Research & Clinical Practice 2011;93(3):328-36. [MEDLINE: 21640424]5656314
129. Crasto W, Khunti K, Jarvis KJ, Skinner TC, Gray LJ, Brela J, et al. Impact of intensive multi-factorial intervention on novel markers of inflammation and vascular stiffness [abstract no: P446]. Diabetic Medicine 2011;28(Suppl 1):166. [EMBASE: 70631246]5656315
130. Crasto WA, Jarvis J, Brela J, Daly H, Gray LJ, Troughton J, et al. Interim analysis of the effects of a multifactorial intervention in people with type 2 diabetes and microalbuminuria after twelve months [abstract no: P410]. Diabetic Medicine 2009;26(Suppl 1):160. [EMBASE: 70342536]5656316
131. Dahl-Jorgensen K, Brinchmann-Hansen O, Hanssen KF, Ganes T, Kierulf P, Smeland E, et al. Effect of near normoglycaemia for two years on progression of early diabetic retinopathy, nephropathy, and neuropathy: the Oslo study. British Medical Journal Clinical Research Ed 1986;293(6556):1195-9. [MEDLINE: 3096429]5656318
132. Dahl-Jorgensen K, Hanssen KF, Kierulf P, Bjoro T, Sandvik L, Aagenaes O. Reduction of urinary albumin excretion after 4 years of continuous subcutaneous insulin infusion in insulin-dependent diabetes mellitus. The Oslo Study. Acta Endocrinologica 1988;117(1):19-25. [MEDLINE: 3289293]5656319
133. Jensen-Urstad K, Reichard P, Jensen-Urstad M. Decreased heart rate variability in patients with type 1 diabetes mellitus is related to arterial wall stiffness. Journal of Internal Medicine 1999;245(1):57-61. [MEDLINE: 10095817]5656321
134. Johansson J, Reichard P, Jensen-Urstad K, Rosfors S, Jensen-Urstad M. Influence of glucose control, lipoproteins, and haemostasis function on brachial endothelial reactivity and carotid intima-media area, stiffness and diameter in Type 1 diabetes mellitus patients. European Journal of Clinical Investigation 2003;33(6):472-9. [MEDLINE: 12795643]5656322
135. Rathsman B, Jensen-Urstad K, Nystrom T. Intensified insulin treatment is associated with improvement in skin microcirculation and ischaemic foot ulcer in patients with type 1 diabetes mellitus: a long-term follow-up study. Diabetologia 2014;57(8):1703-10. [MEDLINE: 24802206]5656323
136. Reichard P. Risk factors for progression of microvascular complications in the Stockholm Diabetes Intervention Study (SDIS). Diabetes Research & Clinical Practice 1992;16(2):151-6. [MEDLINE: 1600854]5656333
137. Reichard P, Berglund B, Britz A, Cars I, Nilsson BY, Rosenqvist U. Intensified conventional insulin treatment retards the microvascular complications of insulin-dependent diabetes mellitus (IDDM): the Stockholm Diabetes Intervention Study (SDIS) after 5 years. Journal of Internal Medicine 1991;230(2):101-8. [MEDLINE: 1865159]5656324
138. Reichard P, Britz A, Carlsson P, Cars I, Lindblad L, Nilsson BY, et al. Metabolic control and complications over 3 years in patients with insulin dependent diabetes (IDDM): the Stockholm Diabetes Intervention Study (SDIS). Journal of Internal Medicine 1990;228(5):511-7. [MEDLINE: 2254723]5656325
139. Reichard P, Britz A, Cars I, Nilsson BY, Sobocinsky-Olsson B, Rosenqvist U. The Stockholm Diabetes Intervention Study (SDIS): 18 months' results. Acta Medica Scandinavica 1988;224(2):115-22. [MEDLINE: 3048052]5656326
140. Reichard P, Jensen-Urstad K, Ericsson M, Jensen-Urstad M, Lindblad LE. Autonomic neuropathy--a complication less pronounced in patients with type 1 diabetes mellitus who have lower blood glucose levels. Diabetic Medicine 2000;17(12):860-6. [MEDLINE: 11168329]5656327
141. Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. New England Journal of Medicine 1993;329(5):304-9. [MEDLINE: 8147960]5656328
142. Reichard P, Pihl M. Mortality and treatment side-effects during long-term intensified conventional insulin treatment in the Stockholm Diabetes Intervention Study. Diabetes 1994;43(2):313-7. [MEDLINE: 8288056]5656330
143. Reichard P, Pihl M, Rosenqvist U, Sule J. Complications in IDDM are caused by elevated blood glucose level: the Stockholm Diabetes Intervention Study (SDIS) at 10-year follow up. Diabetologia 1996;39(12):1483-8. [MEDLINE: 8960830]5656329
144. Reichard P, Rosenqvist U. Nephropathy is delayed by intensified insulin treatment in patients with insulin-dependent diabetes mellitus and retinopathy. Journal of Internal Medicine 1989;226(2):81-7. [MEDLINE: 2671247]5656331
145. Reichard P, Toomingas B, Rosenqvist U. Changes in conceptions and attitudes during five years of intensified conventional insulin treatment in the Stockholm Diabetes Intervention Study (SDIS). Diabetes Educator 1994;20(6):503-8. [MEDLINE: 7851263]5656332
146. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. New England Journal of Medicine 2008;358(6):580-91. [MEDLINE: 18256393]5656335
147. Gaede P, Parving H, Pedersen O. Multifactorial intervention in patients with type 2 diabetes: long-term effects on mortality and vascular complications [abstract no: SA-FC042]. Journal of the American Society of Nephrology 2007;18(Abstracts):43A. [CENTRAL: CN-00740461]5656336
148. Gaede P, Valentine WJ, Palmer AJ, Tucker DM, Lammert M, Parving HH, et al. Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study. Diabetes Care 2008;31(8):1510-5. [MEDLINE: 18443195]5656337
149. Gaede P, Vedel P, Larsen N, Jensen G, Parving HH, Pedersen O. The STENO-2 study: intensified multifactorial intervention reduces the risk of cardiovascular disease in patients with type 2 diabetes and microalbuminuria [abstract no: F-FC031]. Journal of the American Society of Nephrology 2002;13(September, Program & Abstracts):72a. [CENTRAL: CN-00445410]5656338
150. Gaede P, Vedel P, Larsen N, Jensen G, Parving HH, Pedersen O. The Steno-2 study: intensified multifactorial intervention reduces the risk of cardiovascular disease in patients with type 2 diabetes and microalbuminuria [abstract no: 181]. 38th Annual Meeting of the European Association for the Study of Diabetes (EASD); 2002 Sept 1-5; Budapest, Hungary. 2002. 5656339
151. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. New England Journal of Medicine 2003;348(5):383-93. [MEDLINE: 12556541]5656340
152. Gaede P, Vedel P, Obel J, Parving HH, Pedersen O. Intensive multifactorial intervention in NIDDM patients with persistent microalbuminuria [abstract]. Journal of the American Society of Nephrology 1996;7(9):1357. [CENTRAL: CN-00445411]5656341
153. Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999;353(9153):617-22. [MEDLINE: 10030326]5656342
154. Gaede PH, Jepsen PV, Parving HH, Pedersen OB. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno-2 study [Intensiveret multifaktoriel intervention hos patienter med type 2-diabetes mellitus og mikroalbuminuri: Steno-2-studiet]. Ugeskrift for Laeger 1999;161(30):4277-85. [MEDLINE: 10439688]5656343
155. Effect of 6 months of strict metabolic control on eye and kidney function in insulin-dependent diabetics with background retinopathy. Steno Study Group. Lancet 1982;1(8264):121-4. [MEDLINE: 6119509]5656345
156. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.[Erratum appears in Lancet 1999 Aug;354(9178):602]. Lancet 1998;352(9131):837-53. [MEDLINE: 9742976]5656347
157. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia 1991;34(12):877-90. [MEDLINE: 1778353]5656349
158. Turner R, Cull C, Holman R. United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Annals of Internal Medicine 1996;124(1 pt 2):136-45. [MEDLINE: 8554206]5656348
159. Abraira C, Colwell J, Nuttall F, Sawin CT, Henderson W, Comstock JP, et al. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes. Archives of Internal Medicine 1997;157(2):181-8. [MEDLINE: 9009975]5656351
160. Abraira C, Colwell JA, Nuttall FQ, Sawin CT, Nagel NJ, Comstock JP, et al. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes. Diabetes Care 1995;18(8):1113-23. [MEDLINE: 7587846]5656352
161. Abraira C, Emanuele N, Colwell J, Henderson W, Comstock J, Levin S, et al. Glycemic control and complications in type II diabetes. Design of a feasibility trial. VA CS Group (CSDM). Diabetes Care 1992;15(11):1560-71. [MEDLINE: 1308130]5656353
162. Abraira C, Henderson WG, Colwell JA, Nuttall FQ, Comstock JP, Emanuele NV, et al. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM). Diabetes Care 1998;21(4):574-9. [MEDLINE: 9571345]5656354
163. Abraira C, McGuire DK. Intensive insulin therapy in patients with type 2 diabetes: implications of the Veterans affairs (VA CSDM) feasibility trial. American Heart Journal 1999;138(5 Pt 1):S360-5. [MEDLINE: 10539798]5656355
164. Agrawal L, Emanuele NV, Abraira C, Henderson WG, Levin SR, Sawin CT, et al. Ethnic differences in the glycemic response to exogenous insulin treatment in the Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus (VA CSDM). Diabetes Care 1998;21(4):510-5. [MEDLINE: 9571333]5656356
165. Azad N, Emanuele NV, Abraira C, Henderson WG, Colwell J, Levin SR, et al. The effects of intensive glycemic control on neuropathy in the VA cooperative study on type II diabetes mellitus (VA CSDM). Journal of Diabetes & its Complications 1999;13(5-6):307-13. [MEDLINE: 10765007]5656357
166. Emanuele N, Azad N, Abraira C, Henderson W, Colwell J, Levin S, et al. Effect of intensive glycemic control on fibrinogen, lipids, and lipoproteins: Veterans Affairs Cooperative Study in Type II Diabetes Mellitus. Archives of Internal Medicine 1998;158(22):2485-90. [MEDLINE: 9855387]5656358
167. Emanuele N, Klein R, Abraira C, Colwell J, Comstock J, Henderson WG, et al. Evaluations of retinopathy in the VA Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM). A feasibility study. Diabetes Care 1996;19(12):1375-81. [MEDLINE: 8941467]5656359
168. Levin SR, Coburn JW, Abraira C, Henderson WG, Colwell JA, Emanuele NV, et al. Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes Feasibility Trial Investigators. Diabetes Care 2000;23(10):1478-85. [MEDLINE: 11023140]5656360
169. Pitale S, Kernan-Schroeder D, Emanuele N, Sawin C, Sacks J, Abraira C, et al. Health-related quality of life in the VA Feasibility Study on glycemic control and complications in type 2 diabetes mellitus. Journal of Diabetes & its Complications 2005;19(4):207-11. [MEDLINE: 15993354]5656361
170. Pitale SU, Abraira C, Emanuele NV, McCarren M, Henderson WG, Pacold I, et al. Two years of intensive glycemic control and left ventricular function in the Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus (VA CSDM). Diabetes Care 2000;23(9):1316-20. [MEDLINE: 10977025]5656362
171. Abraira C, Duckworth W, McCarren M, Emanuele N, Arca D, Reda D, et al. Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial. Journal of Diabetes & its Complications 2003;17(6):314-22. [MEDLINE: 14583175]5656364
172. Abraira C, Duckworth WC, Moritz T, VADT Group. Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim report. Diabetes, Obesity & Metabolism 2009;11(2):150-6. [MEDLINE: 18671796]5656365
173. Agrawal L, Azad N, Emanuele NV, Bahn GD, Kaufman DG, Moritz TE, et al. Observation on renal outcomes in the Veterans Affairs Diabetes Trial. Diabetes Care 2011;34(9):2090-4. [MEDLINE: 21775749]5656366
174. Alele JD, Luttrell LM, Hollis BW, Luttrell DK, Hunt KJ, VADT Study Group. Relationship between vitamin D status and incidence of vascular events in the Veterans Affairs Diabetes Trial. Atherosclerosis 2013;228(2):502-7. [MEDLINE: 23608249]5656367
175. Anderson RJ, Bahn GD, Emanuele NV, Marks JB, Duckworth WC, VADT Study Group. Blood pressure and pulse pressure effects on renal outcomes in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care 2014;37(10):2782-8. [MEDLINE: 25048382]5656368
176. Anderson RJ, Bahn GD, Moritz TE, Kaufman D, Abraira C, Duckworth W, et al. Blood pressure and cardiovascular disease risk in the Veterans Affairs Diabetes Trial. Diabetes Care 2011;34(1):34-8. [MEDLINE: 21059830]5656369
177. Azad N, Agrawal L, Emanuele NV, Klein R, Bahn GD, McCarren M, et al. Association of PAI-1 and fibrinogen with diabetic retinopathy in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care 2014;37(2):501-6. [MEDLINE: 24101699]5656370
178. Azad N, Agrawal L, Emanuele NV, Klein R, Bahn GD, Reaven P, et al. Association of blood glucose control and pancreatic reserve with diabetic retinopathy in the Veterans Affairs Diabetes Trial (VADT). Diabetologia 2014;57(6):1124-31. [MEDLINE: 24599110]5656371
179. Azar M, Lyons TJ, Alaupovic P, Stoner JA, Quiroga C, Kaufman DG, et al. Apolipoprotein-defined and NMR lipoprotein subclasses in the veterans affairs diabetes trial. Journal of Diabetes & its Complications 2013;27(6):627-32. [MEDLINE: 23911536]5656372
180. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven P, et al. Glucose control and vascular complications in veterans with type 2 diabetes.[Erratum appears in N Engl J Med. 2009 Sep 3;361(10):1028], [Erratum appears in N Engl J Med. 2009 Sep 3;361(10):1024-5; PMID: 19726779]. New England Journal of Medicine 2009;360(2):129-39. [MEDLINE: 19092145]5656373
181. Duckworth WC, Abraira C, Moritz TE, Davis SN, Emanuele N, Goldman S, et al. The duration of diabetes affects the response to intensive glucose control in type 2 subjects: the VA Diabetes Trial. Journal of Diabetes & its Complications 2011;25(6):355-61. [MEDLINE: 22055259]5656374
182. Duckworth WC, McCarren M, Abraira C, VA Diabetes Trial. Glucose control and cardiovascular complications: the VA Diabetes Trial. Diabetes Care 2001;24(5):942-5. [MEDLINE: 11347758]5656375
183. Duckworth WC, McCarren M, Abraira C, VADT Investigators. Control of cardiovascular risk factors in the Veterans Affairs Diabetes Trial in advanced type 2 diabetes. Endocrine Practice 2006;12 Suppl 1:85-8. [MEDLINE: 16627388]5656376
184. Emanuele N, Klein R, Moritz T, Davis MD, Glander K, Anderson R, et al. Comparison of dilated fundus examinations with seven-field stereo fundus photographs in the Veterans Affairs Diabetes Trial. Journal of Diabetes & its Complications 2009;23(5):323-9. [MEDLINE: 18406632]5656377
185. Emanuele N, Moritz T, Klein R, Davis MD, Glander K, Khanna A, et al. Ethnicity, race, and clinically significant macular edema in the Veterans Affairs Diabetes Trial (VADT). Diabetes Research & Clinical Practice 2009;86(2):104-10. [MEDLINE: 19720420]5656378
186. Emanuele N, Sacks J, Klein R, Reda D, Anderson R, Duckworth W, et al. Ethnicity, race, and baseline retinopathy correlates in the veterans affairs diabetes trial. Diabetes Care 2005;28(8):1954-8. [MEDLINE: 16043738]5656379
187. Hayward RA, Reaven PD, Wiitala WL, Bahn GD, Reda DJ, Ge L, et al. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes.[Erratum appears in N Engl J Med. 2015 Jul 9;373(2):198; PMID: 26154808]. New England Journal of Medicine 2015;372(23):2197-206. [MEDLINE: 26039600]5656380
188. Jenkins AJ, Fu D, Azar M, Stoner JA, Kaufman DG, Zhang S, et al. Clinical correlates of serum pigment epithelium-derived factor in type 2 diabetes patients. Journal of Diabetes & its Complications 2014;28(3):353-9. [MEDLINE: 24560422]5656381
189. Kirkman MS, McCarren M, Shah J, Duckworth W, Abraira C, VADT Study Group. The association between metabolic control and prevalent macrovascular disease in Type 2 diabetes: the VA Cooperative Study in diabetes. Journal of Diabetes & its Complications 2006;20(2):75-80. [MEDLINE: 16504835]5656382
190. Koska J, Saremi A, Bahn G, Yamashita S, Reaven PD, Veterans Affairs Diabetes Trial Investigators. The effect of intensive glucose lowering on lipoprotein particle profiles and inflammatory markers in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care 2013;36(8):2408-14. [MEDLINE: 23536583]5656383
191. Lopes-Virella MF, Hunt KJ, Baker NL, Virella G, Moritz T, VADT Investigators. The levels of MDA-LDL in circulating immune complexes predict myocardial infarction in the VADT study. Atherosclerosis 2012;224(2):526-31. [MEDLINE: 22963984]5656384
192. Meyers CD, McCarren M, Wong ND, Abraira C, Duckworth WC, Kashyap ML, et al. Baseline achievement of lipid goals and usage of lipid medications in patients with diabetes mellitus (from the Veterans Affairs Diabetes Trial). American Journal of Cardiology 2006;98(1):63-5. [MEDLINE: 16784922]5656385
193. Moritz T, Duckworth W, Abraira C. Veterans Affairs diabetes trial--corrections.[Erratum for N Engl J Med. 2009 Jan 8;360(2):129-39; PMID: 19092145]. New England Journal of Medicine 2009;361(10):1024-5. [MEDLINE: 19726779]5656386
194. Reaven PD, Emanuele N, Moritz T, Klein R, Davis M, Glander K, et al. Proliferative diabetic retinopathy in type 2 diabetes is related to coronary artery calcium in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care 2008;31(5):952-7. [MEDLINE: 18316393]5656387
195. Reaven PD, Moritz TE, Schwenke DC, Anderson RJ, Criqui M, Detrano R, et al. Intensive glucose-lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis. Diabetes 2009;58(11):2642-8. [MEDLINE: 19651816]5656388
196. Saremi A, Anderson RJ, Luo P, Moritz TE, Schwenke DC, Allison M, et al. Association between IL-6 and the extent of coronary atherosclerosis in the veterans affairs diabetes trial (VADT). Atherosclerosis 2009;203(2):610-4. [MEDLINE: 18804762]5656389
197. Saremi A, Bahn G, Reaven PD, VADT Investigators. Progression of vascular calcification is increased with statin use in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care 2012;35(11):2390-2. [MEDLINE: 22875226]5656390
198. Saremi A, Moritz TE, Anderson RJ, Abraira C, Duckworth WC, Reaven PD, et al. Rates and determinants of coronary and abdominal aortic artery calcium progression in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care 2010;33(12):2642-7. [MEDLINE: 20807873]5656391
199. Saremi A, Schwenke DC, Bahn G, Ge L, Emanuele N, Reaven PD, et al. The effect of intensive glucose lowering therapy among major racial/ethnic groups in the Veterans Affairs Diabetes Trial. Metabolism: Clinical & Experimental 2015;64(2):218-25. [MEDLINE: 25456099]5656392
200. Zimering MB, Anderson RJ, Ge L, Moritz TE, Investigators for the VADT. Increased plasma basic fibroblast growth factor is associated with coronary heart disease in adult type 2 diabetes mellitus. Metabolism: Clinical & Experimental 2011;60(2):284-91. [MEDLINE: 20206949]5656393
201. Zimering MB, Anderson RJ, Luo P, Moritz TE, Investigators for the Veterans Affairs Diabetes Trial. Plasma basic fibroblast growth factor is correlated with plasminogen activator inhibitor-1 concentration in adults from the Veterans Affairs Diabetes Trial. Metabolism: Clinical & Experimental 2008;57(11):1563-9. [MEDLINE: 18940395]5656394
202. Zimering MB, Anderson RJ, Moritz TE, Ge L, Investigators for the VADT. Endothelial cell inhibitory autoantibodies are associated with laser photocoagulation in adults from the Veterans Affairs Diabetes Trial. Metabolism: Clinical & Experimental 2009;58(6):882-7. [MEDLINE: 19375761]5656395
203. Zimering MB, Anderson RJ, Moritz TE, Ge L, Investigators for the VADT. Low plasma basic fibroblast growth factor is associated with laser photocoagulation treatment in adult type 2 diabetes mellitus from the Veterans Affairs Diabetes Trial. Metabolism: Clinical & Experimental 2009;58(3):393-400. [MEDLINE: 19217457]5656396
204. Zimering MB, Pan Z. Autoantibodies in type 2 diabetes induce stress fiber formation and apoptosis in endothelial cells. Journal of Clinical Endocrinology & Metabolism 2009;94(6):2171-7. [MEDLINE: 19293267]5656397
205. Christiansen JS, Ingerslev J, Bernvil SS, Christensen CK, Hermansen K, Schmitz A. Near normoglycemia for 1 year has no effect on platelet reactivity, factor VIII, and von Willebrand factor in insulin-dependent diabetes mellitus: a controlled trial. Journal of Diabetic Complications 1987;1(3):100-6. [MEDLINE: 2969906]5656399
206. Holman RR, Dornan TL, Mayon-White V, Howard-Williams J, Orde-Peckar C, Jenkins L, et al. Prevention of deterioration of renal and sensory-nerve function by more intensive management of insulin-dependent diabetic patients. A two-year randomised prospective study. Lancet 1983;1(8318):204-8. [MEDLINE: 6130244]5656401
207. Kawamori R, Kamado K, Kamada T. Recent progress in the treatment of diabetic nephropathy: importance of strict glycemic control on the regression of diabetic nephropathy. Journal of Diabetic Complications 1991;5(2-3):88-90. [MEDLINE: 1770063]5656403
208. Wiseman MJ, Saunders AJ, Keen H, Viberti G. Effect of blood glucose control on increased glomerular filtration rate and kidney size in insulin-dependent diabetes. New England Journal of Medicine 1985;312(10):617-21. [MEDLINE: 3883162]5656405
209. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf (accessed 8 April 2017).
210. Desouza C, Salazar H, Cheong B, Murgo J, Fonseca V. Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring. Diabetes Care 2003;26(5):1485-9. [MEDLINE: 12716809]
211. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes.[Erratum appears in N Engl J Med. 2009 Sep 3;361(10):1028], [Erratum appears in N Engl J Med. 2009 Sep 3;361(10):1024-5; PMID: 19726779]. New England Journal of Medicine 2009;360(2):129-39. [MEDLINE: 19092145]
212. Finne P, Reunanen A, Stenman S, Groop PH, Grönhagen-Riska C. Incidence of end-stage renal disease in patients with type 1 diabetes. JAMA 2005;294(14):1782-7. [MEDLINE: 16219881]
213. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, et al. Effects of intensive glucose lowering in type 2 diabetes. New England Journal of Medicine 2008;358(24):2545-59. [MEDLINE: 18539917]
214. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-6. [MEDLINE: 18436948]
215. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383-94. [MEDLINE: 21195583]
216. Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal T, Hemmingsen C, et al. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ 2011;343:d6898. [MEDLINE: 22115901]
217. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60. [MEDLINE: 12958120]
218. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
219. International Diabetes Federation. IDF Diabetes atlas (7th edition), 2015. www.diabetesatlas.org/ (accessed 8 April 2017).
220. Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.[Erratum appears in Lancet. 2010 Oct 30;376(9751):1466]. Lancet 2010;376(9739):419-30. [MEDLINE: 20594588]
221. Krolewski AS, Laffel LM, Krolewski M, Quinn M, Warram JH. Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. New England Journal of Medicine 1995;332(19):1251-5. [MEDLINE: 7708068]
222. Moritz T, Duckworth W, Abraira C. Veterans affairs diabetes trial - corrections.[Erratum for N Engl J Med. 2009 Jan 8;360(2):129-39; PMID: 19092145]. New England Journal of Medicine 2009;361(10):1024-5. [MEDLINE: 19726779]
223. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years(DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.[Erratum appears in Lancet. 2013 Feb 23;381(9867):628 Note: AlMazroa, Mohammad A [added]; Memish, Ziad A [added]]. Lancet 2012;380(9859):2197-223. [MEDLINE: 23245608]
224. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New England Journal of Medicine 2008;358(24):2560-72. [MEDLINE: 18539916]
225. Paterson BL, Thorne S, Dewis M. Adapting to and managing diabetes. Image - the Journal of Nursing Scholarship 1998;30(1):57-62. [MEDLINE: 9549943]
226. Pavkov ME, Bennett PH, Knowler WC, Krakoff J, Sievers ML, Nelson RG. Effect of youth-onset type 2 diabetes mellitus on incidence of end-stage renal disease and mortality in young and middle-aged Pima Indians. JAMA 2006;26(296):421-6. [MEDLINE: 16868300]
227. Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. New England Journal of Medicine 1999;341(15):1127-33. [MEDLINE: 10511612]
228. Schünemann HJ, Oxman AD, Higgins JP, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
229. Schünemann HJ, Oxman AD, Higgins JP, Deeks JJ, Glasziou P, Guyatt GH. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
230. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.[Erratum appears in Lancet 1999 Aug 14;354(9178):602]. Lancet 1998;352(9131):837-53. [MEDLINE: 9742976]
231. US Renal Data System. USRDS 2011 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases. 2011. www.usrds.org/atlas11.aspx (accessed 8 April 2017).
232. US Renal Data System. 2013 atlas of CKD and ESRD. www.usrds.org/atlas13.aspx (accessed 8 April 2017).
233. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27(5):1047-53. [MEDLINE: 15111519]
234. De Cosmo S, Pacilli A, Lamacchia O, Cignarelli M, Fioretto P, Vecchio M, et al. Glucose targets for preventing diabetic kidney disease and its progression. Cochrane Database of Systematic Reviews 2012, Issue 10. [DOI: 10.1002/14651858.CD010137]